Molecular predictors of efficacy of adjuvant weekly paclitaxel in early breast cancer

Autor: Enrique de Alava, A Murias, Manuel Ruiz-Borrego, Norberto Batista, Ana Santaballa, C. Crespo, Ricardo Cubedo, J. Florián, Miguel Martin, Maria José Ruíz García, César A. Rodríguez, Lourdes Calvo, Rosalía Caballero, S. Dominguez, Emilio Alba, Maria Jose Godes, M. Mendez, Amparo Ruiz, Cristina Llorca, Álvaro Rodríguez-Lescure, M. Abad
Přispěvatelé: Servicio de Oncología Médica, Departmento de Oncología, Hospital General Universitario Gregorio Marañón, Department of Medical Oncology, Hospital Universitario de Elche, Instituto Valenciano de Oncologia, Hospital Virgen de la Victoria, Complexo Hospitalario Universitario A Coruña, Hospital Universitario Virgen del Rocío [Sevilla], Hospital La Fe, Hospital Universitario de Salamanca, Hospital Universitario Ramón y Cajal [Madrid], Universidad de Alcalá - University of Alcalá (UAH)-Universidad de Alcalá - University of Alcalá (UAH), Department of Cellular Biology and Pathology, Facultad de Medicina, Universidad de Salamanca, Hospital Txagorritxu, Hospital Comarcal Barbastro, Hospital de Elda, Hospital General de Móstoles, Hospital General Universitario de Valencia, Hospital Puerta de Hierro, Hospital Universitario Insular, Hospital Universitario De Canarias, Hospital General de Ciudad Real (HGUCR), University of Castilla-La Mancha (UCLM)-University of Castilla-La Mancha (UCLM), GEICAM, Molecular Pathology, Centro de Investigación del Cancer-IBMCC, Universidad de Salamanca- CSIC
Rok vydání: 2009
Předmět:
Oncology
Cancer Research
Pathology
Receptor
ErbB-2
medicine.medical_treatment
Kaplan-Meier Estimate
chemistry.chemical_compound
0302 clinical medicine
Breast cancer
Antineoplastic Combined Chemotherapy Protocols
In Situ Hybridization
Fluorescence
0303 health sciences
Prognosis
Molecular predictors of efficacy
Immunohistochemistry
3. Good health
Treatment Outcome
Paclitaxel
Receptors
Estrogen
Chemotherapy
Adjuvant
030220 oncology & carcinogenesis
Female
Breast disease
Fluorouracil
Receptors
Progesterone
Adjuvant
medicine.drug
Epirubicin
medicine.medical_specialty
Cyclophosphamide
Antineoplastic Agents
Breast Neoplasms
Adjuvant paclitaxel
Disease-Free Survival
03 medical and health sciences
Internal medicine
medicine
Biomarkers
Tumor
Humans
030304 developmental biology
Chemotherapy
business.industry
Cancer
medicine.disease
chemistry
business
Zdroj: Breast Cancer Research and Treatment
Breast Cancer Research and Treatment, Springer Verlag, 2009, 123 (1), pp.149-157. ⟨10.1007/s10549-009-0663-z⟩
BREAST CANCER RESEARCH AND TREATMENT
r-FISABIO. Repositorio Institucional de Producción Científica
instname
r-FISABIO: Repositorio Institucional de Producción Científica
Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)
Digital.CSIC. Repositorio Institucional del CSIC
ISSN: 1573-7217
0167-6806
DOI: 10.1007/s10549-009-0663-z⟩
Popis: Treatment with fluororacil, epirubicin, and cyclophosphamide followed by weekly paclitaxel (FEC-P) yielded superior disease-free survival than FEC in the adjuvant breast cancer trial GEICAM 9906. We evaluate molecular subtypes predictive of prognosis and paclitaxel response in this trial. Two molecular subtype classifications based on conventional immunohistochemical and fluorescent in situ hybridization determinations were used: #1: Four groups segregated according to the combination of hormone receptor (HR) and HER2 status; #2: Intrinsic subtype classification (Triple Negative (TN), HER2, Luminal B and Luminal A). Results: Both subtype classifications yielded prognostic and predictive information. HR +/HER2- patients (and Luminal A patients) had a significantly better outcome than the other subgroups of patients. The superiority of FEC-P over FEC was clearly more marked in HR-/HER2- patients (TN patients), particularly in the subset with basal phenotype (TN and either EGFR+ or cytokeratins 5/6+). The Luminal A subtype also achieved a significant benefit with FEC-P. The molecular-defined subgroup of TN was clearly predictive of better response to treatment with FEC-P. Luminal A patients had the best prognosis and also have a better outcome with weekly paclitaxel.
This work was supported, in part, by grants from Bristol- Myers Squibb and Pharmacia.
Databáze: OpenAIRE
Externí odkaz: